Immediate Impact
1 from Science/Nature 63 standout
Citing Papers
A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX
2025 Standout
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
2024 Standout
Works of Philip Austin being referenced
All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes
2023
Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity
2023
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Philip Austin | 66 | 164 | 35 | 129 | 90 | 21 | 432 | |
| Xulong Sun | 137 | 150 | 32 | 112 | 69 | 29 | 452 | |
| Roberto Lugo | 133 | 123 | 30 | 40 | 33 | 28 | 478 | |
| Kiyoung Lee | 52 | 128 | 36 | 76 | 119 | 18 | 409 | |
| Ji-Yeon Lee | 61 | 108 | 23 | 23 | 100 | 24 | 415 | |
| Xingxin Xu | 37 | 175 | 41 | 60 | 45 | 23 | 450 | |
| Lizhen Shan | 83 | 180 | 52 | 111 | 65 | 17 | 447 | |
| Jaehee Kim | 85 | 196 | 16 | 32 | 88 | 28 | 410 | |
| Junhua Ma | 28 | 226 | 25 | 173 | 67 | 24 | 423 | |
| Cheng Ho | 84 | 222 | 27 | 65 | 69 | 25 | 501 | |
| Jiangtao Yan | 65 | 149 | 87 | 61 | 79 | 23 | 444 |
All Works
Login with ORCID to disown or claim papers
Loading papers...